Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations

Discontinued Operations

3 Months Ended

Mar. 31, 2021

9. Discontinued Operations

The components of loss from discontinued operations as reported in our statements of operations were as follows:


	Three months ended
	March 31, 2020
(In thousands, except per share data)
Revenue:
Product revenue	$	210

Costs and expenses:
Cost of goods sold		171
Research and development		465
Selling, general and administrative		1,825
Total costs and expenses		2,461
Loss from discontinued operations		(2,251)
Other expense		—
Net loss from discontinued operations	$	(2,251)
Basic and diluted net loss per common share from discontinued operations	$	(0.82)
Weighted average shares used in computing basic and diluted net loss per common share		2,755

The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:


	March 31,		December 31,
	2021		2020
(In thousands)
Prepaid expenses and other current assets		128		181
Discontinued operations – current assets	$	128	$	181

Accounts payable	$	1,518	$	1,515
Accrued clinical trials expenses		9		80
Accrued sales allowances		57		61
Other accrued liabilities		309		304
Discontinued operations – current liabilities	$	1,893	$	1,960

During the three months ended March 31, 2020 we recognized non-cash stock-based compensation expenses of approximately $24,000 which is included in discontinued operations.